Posts tagged merger
Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group analyst Jason Kolbert.

The mechanism of action of Ciclofilin’s antiviral asset, CPI-431-32, should be complementary to ContraVir’s CMX157 by inhibiting distinct critical steps in the viral life cycle, he said.

Read More